AI-Generated Content Disclosure (CA AB 3030) — This article was researched and drafted by Mentis Intelligence, an AI system operated by Carlo P. Honrado M.D., Inc. It is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Its material claims are checked against cited public sources under the governed publishing policy. No physician authorship or individualized clinical judgment is claimed. To speak with a human member of our team, please contact us online or call our office directly.

Short-Acting Neuromodulator Approved in Canada for Frown Lines

Health Canada approved Boey® (trenibotulinumtoxinE) on June 23, 2026, making Canada the first country to authorize a short-acting injectable neuromodulator designed to work quickly and fade within two to three weeks.

According to Allergan Aesthetics, an AbbVie company, as reported by Cosmetiq Medicine, Boey is approved in Canada for the temporary improvement of moderate to severe glabellar lines in adults. Glabellar lines are the vertical “frown lines” that form between the eyebrows, often becoming more visible with repeated facial expression.

The approval is notable because Boey represents a different product concept from traditional Botox-style neuromodulators: instead of aiming for results that last several months, it is intentionally designed as a shorter-duration option.

What Is a Short-Acting Neuromodulator?

A neuromodulator is an injectable medication that temporarily reduces targeted muscle activity to soften expression-related facial lines. In aesthetics, botulinum toxin products are commonly used for areas such as frown lines, forehead lines, and crow’s feet, depending on the product’s approved indications and the treating clinician’s judgment.

Boey is a botulinum toxin type E neuromodulator, also known as trenibotulinumtoxinE. According to Allergan Aesthetics, it is described as fast acting, with visible results possible in as little as eight hours, and effects that fade within two to three weeks.

That duration is the key distinction. Traditional botulinum toxin type A neuromodulators typically last about three to four months. Boey’s shorter timeline suggests a new category in which duration itself becomes part of treatment selection.

Why Is the Boey Approval Important for Aesthetic Patients?

The Boey approval matters because it signals a shift toward more flexible injectable options, even though the product is currently approved only in Canada.

For prospective patients, the most important takeaway is not that a new treatment is immediately available in the United States. It is not. Rather, the approval suggests that future injectable planning may become more personalized by duration, onset, and patient comfort level.

Potential implications include:

1. A lower-commitment introduction to neuromodulators
   Some patients are hesitant to try neuromodulators because they do not want a result that lasts several months. A short-acting option may eventually appeal to people who want to “test drive” the look and feel of reduced frown-line movement.

2. More event-based timing possibilities
   According to Allergan Aesthetics, Boey may show visible results in as little as eight hours and fade within two to three weeks. If similar products become available more broadly, shorter-duration injectables could be discussed for time-limited events such as photography, weddings, public appearances, or media work.

3. A different reassurance profile for cautious patients
   Some people worry about looking “frozen” or feeling stuck with an unfamiliar appearance. A product designed to wear off quickly may reduce that psychological barrier for some patients, although safety, suitability, and expectations still require discussion with a qualified medical professional.

4. A new direction for injectable innovation
   The approval is being described as the global debut of a short-acting neurotoxin category. Rather than competing mainly on longer duration, this category emphasizes flexibility and reversibility over a shorter period.

Is Boey Available in the United States?

No. As of June 29, 2026, Boey is approved in Canada only and is not approved or available in the United States.

According to Allergan Aesthetics, provider training and commercial rollout are beginning in Canada, and trenibotulinumtoxinE is under regulatory review in multiple other countries. There is no confirmed U.S. launch timeline.

For U.S. patients, this means there is no immediate change in available neuromodulator treatments. The approval is best understood as a preview of where the field may be heading, not as a current domestic treatment option.

How Does This Differ From Traditional Botox-Style Treatments?

Traditional neuromodulator treatments are generally used when patients want a result that lasts several months. These products can be appropriate for people seeking sustained softening of expression-related lines, depending on their goals, anatomy, medical history, and the clinician’s assessment.

Boey is different because it is positioned as a short-term option. According to Allergan Aesthetics, its effect fades within two to three weeks. That shorter duration may eventually create a separate category for patients who want:

• A brief trial before considering longer-lasting treatment
• A temporary option before a specific event
• A shorter commitment if they are new to neuromodulators
• More flexibility in adjusting future aesthetic plans

It is not being framed as a replacement for longer-lasting neuromodulators. Instead, it may become part of a broader menu of choices if approved in additional markets.

What Should Patients Ask Before Considering Emerging Injectables?

Patients hearing about short-acting neuromodulators should understand that regulatory status, availability, training, and clinical suitability vary by country and product.

Helpful questions to ask a qualified physician include:

1. Is this product approved in my country for my concern?
2. What are the expected onset and duration?
3. What clinical data support its safety and effectiveness?
4. How does it compare with longer-lasting neuromodulators?
5. What are the realistic benefits, limitations, and possible risks?

Emerging devices, injectables, and techniques should be treated as developments to discuss—not endorsements or one-size-fits-all recommendations.

FAQ

What is Boey?

Boey is a botulinum toxin type E neuromodulator, also called trenibotulinumtoxinE. Health Canada approved it for temporary improvement of moderate to severe glabellar lines in adults.

How quickly does Boey work?

According to Allergan Aesthetics, visible results may appear in as little as eight hours after treatment.

How long does Boey last?

Boey is designed to fade within two to three weeks. That is shorter than traditional botulinum toxin type A neuromodulators, which typically last about three to four months.

Can patients in the United States get Boey now?

No. As of late June 2026, Boey is approved in Canada only and is not approved or available in the United States.

Does a shorter duration mean it is safer?

Not necessarily. Duration is only one feature of a medication. Safety depends on the product’s clinical data, approved use, patient selection, dosing, injection technique, and post-marketing monitoring.

This article was produced by Mentis Intelligence for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual results vary. New techniques and devices should be discussed with a qualified physician. For a consultation with Dr. Carlo Honrado MD, FACS, contact (310) 286-0043 or visit drhonrado.com/contact. Content generated by AI (Mentis Intelligence) per California AB 3030 disclosure requirement.

To discuss injectable options and treatment timing in Beverly Hills or Century City, request a consultation.

Stay Connected

Questions about your care options?

Our team is here to answer your questions and guide you toward the right next step — in a private, unhurried consultation.